- Home
- APLS vs CZR Comparison
APLS vs CZR Comparison
Compare APLS & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLS | CZR |
|---|---|---|
| Founded | 2009 | 1937 |
| Country | United States | United States |
| Employees | N/A | 15500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.1B |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | APLS | CZR |
|---|---|---|
| Price | $40.96 | $27.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 21 | 13 |
| Target Price | ★ $33.59 | $31.92 |
| AVG Volume (30 Days) | ★ 3.8M | 3.1M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.50 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | $1,003,782,000.00 | ★ $1,473,504,000.00 |
| Revenue This Year | N/A | $3.56 |
| Revenue Next Year | $18.19 | $2.48 |
| P/E Ratio | $204.78 | ★ N/A |
| Revenue Growth | 28.46 | ★ 65.03 |
| 52 Week Low | $16.10 | $17.86 |
| 52 Week High | $41.00 | $31.58 |
Technical Indicators
Market Signals| Indicator | APLS | CZR |
|---|---|---|
| Relative Strength Index (RSI) | 86.68 | 57.35 |
| Support Level | $19.29 | $24.74 |
| Resistance Level | $40.98 | $28.80 |
| Average True Range (ATR) | 0.06 | 0.90 |
| MACD | -0.75 | -0.05 |
| Stochastic Oscillator | 82.50 | 63.46 |
Price Performance
Historical ComparisonAbout APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
About CZR Caesars Entertainment Inc.
Caesars Entertainment includes about 50 domestic gaming properties across the Las Vegas (47% of the estimated 2025 EBITDAR before corporate expenses) and regional (49%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2024. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform.